日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Rationale and design of MUSIC-HFpEF: a phase 1b, pilot trial evaluating the safety and pharmacodynamic effects of AAV1.SERCA2A in heart failure with preserved ejection fraction

MUSIC-HFpEF 研究的原理和设计:一项 1b 期试点试验,旨在评估 AAV1.SERCA2A 在射血分数保留型心力衰竭中的安全性和药效学作用。

Fudim, Marat; Sarma, Satyam; MacNamara, James P; Ascheim, Deborah D; Kittipibul, Veraprapas; Doukellis, Katheryn; Dhimitri, Andy; Fitzhugh, Robert; Kamat, Niharika; Costa, Kevin D; Rudy, Jeffrey; Guerrero, Janet; Chan, Camie; Li, Ronald A; Bavry, Anthony A; Patel, Manesh R; Grodin, Justin L; Levine, Benjamin D; Hajjar, Roger J

Clinical and financial implications of inpatient and outpatient management of worsening heart failure

住院和门诊治疗恶化性心力衰竭的临床和经济影响

Greene, Stephen J; Kaltenbach, Lisa A; Fonarow, Gregg C; Chiswell, Karen; Kittipibul, Veraprapas; Haywood, Hubert B; Khan, Muhammad Shahzeb; Hammill, Bradley G; Butler, Javed; Hernandez, Adrian F; Felker, G Michael

Atrial Mechanics in Heart Failure With Preserved Ejection Fraction: Effect of a No-Implant Interatrial Shunt

射血分数保留型心力衰竭患者的心房力学:非植入式心房分流术的影响

Laufer-Perl, Michal; Flint, Nir; Arbel, Yaron; Alenezi, Fawaz; Kittipibul, Veraprapas; Yaranov, Dmitry; Shaburishvili, Tamaz; Amin, Rohit; Fudim, Marat

Post-COVID-19 cardiovascular disease risk in kidney transplant recipients

肾移植受者感染新冠病毒后发生心血管疾病的风险

Bowring, Mary G; Manothummetha, Kasama; Kittipibul, Veraprapas; Li, Lucy X; Avery, Robin K; Cochran, Willa; Ellis, Sean; Wittstein, Ilan S; Segev, Dorry L; Durand, Christine M; Brennan, Daniel C; Permpalung, Nitipong

Assessing congestion using estimated plasma volume status: Ready for prime time?

利用估计血浆容量状态评估充血:准备好迎接黄金时代了吗?

Wattanachayakul, Phuuwadith; Kittipibul, Veraprapas; Fudim, Marat

Understanding the variability in red cell and plasma volume combinations can help guide management in heart failure

了解红细胞和血浆容量组合的变异性有助于指导心力衰竭的治疗。

Miller, Wayne L; Fudim, Marat; Kittipibul, Veraprapas; Yaranov, Dmitry M; Carry, Brendan J; Silver, Marc A

Projecting the benefit of vericiguat in PARADIGM-HF and DAPA-HF populations: Insights from the VICTORIA trial

预测维利西呱在 PARADIGM-HF 和 DAPA-HF 人群中的获益:来自 VICTORIA 试验的启示

Kittipibul, Veraprapas; Mentz, Robert J; Young, Rebecca; Butler, Javed; Ezekowitz, Justin A; Lam, Carolyn S P; Ponikowski, Piotr; Voors, Adriaan; Corda, Stefano; McMullan, Ciaran; O'Connor, Christopher M; Anstrom, Kevin J; Armstrong, Paul W

Invasive haemodynamic assessment in heart failure with preserved ejection fraction

射血分数保留型心力衰竭的侵入性血流动力学评估

Wattanachayakul, Phuuwadith; Kittipibul, Veraprapas; Salah, Husam M; Yaku, Hidenori; Gustafsson, Finn; Baratto, Claudia; Caravita, Sergio; Fudim, Marat

Pulmonary artery pressure trajectories in heart failure patients treated with GLP-1 receptor agonists

接受 GLP-1 受体激动剂治疗的心力衰竭患者的肺动脉压力变化轨迹

Jiang, Haoran; Wattanachayakul, Phuuwadith; Kittipibul, Veraprapas; Nicolsen, Erika; McVeigh, Todd; Kamneva, Oksana; Fudim, Marat

Clinical endpoints in pragmatic heart failure trials: From data collection to clinical endpoint classification

实用性心力衰竭试验中的临床终点:从数据收集到临床终点分类

Kittipibul, Veraprapas; Van Spall, Harriette G C; Jones, William Schuyler; Fudim, Marat; Mentz, Robert J; Anstrom, Kevin; Pitt, Bertram; Desvigne-Nickens, Patrice; Fleg, Jerome L; Hage, Camilla; James, Stefan; Held, Claes; Lund, Lars; DeVore, Adam